Announcement • Mar 31
Baotou Dongbao Bio-Tech Co.,Ltd to Report Q1, 2026 Results on Apr 24, 2026 Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report Q1, 2026 results on Apr 24, 2026 New Risk • Mar 30
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 23% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Reported Earnings • Mar 30
Full year 2025 earnings released: EPS: CN¥0.093 (vs CN¥0.14 in FY 2024) Full year 2025 results: EPS: CN¥0.093 (down from CN¥0.14 in FY 2024). Revenue: CN¥745.3m (down 16% from FY 2024). Net income: CN¥54.3m (down 37% from FY 2024). Profit margin: 7.3% (down from 9.7% in FY 2024). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Announcement • Mar 29
Baotou Dongbao Bio-Tech Co.,Ltd, Annual General Meeting, Apr 28, 2026 Baotou Dongbao Bio-Tech Co.,Ltd, Annual General Meeting, Apr 28, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Baotou, Inner Mongolia China Announcement • Dec 31
Baotou Dongbao Bio-Tech Co.,Ltd to Report Fiscal Year 2025 Results on Mar 30, 2026 Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report fiscal year 2025 results on Mar 30, 2026 Reported Earnings • Oct 29
Third quarter 2025 earnings released: EPS: CN¥0.02 (vs CN¥0.025 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.02 (down from CN¥0.025 in 3Q 2024). Revenue: CN¥163.7m (down 13% from 3Q 2024). Net income: CN¥11.5m (down 23% from 3Q 2024). Profit margin: 7.0% (down from 7.9% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year whereas the company’s share price has fallen by 12% per year. Announcement • Sep 30
Baotou Dongbao Bio-Tech Co.,Ltd to Report Q3, 2025 Results on Oct 29, 2025 Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report Q3, 2025 results on Oct 29, 2025 New Risk • Aug 29
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.4% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Board Change • Jul 25
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Jing Wang was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Jul 02
Baotou Dongbao Bio-Tech Co.,Ltd to Report First Half, 2025 Results on Aug 29, 2025 Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report first half, 2025 results on Aug 29, 2025 Announcement • Apr 25
Baotou Dongbao Bio-Tech Co.,Ltd Proposes Final Cash Dividend for 2024 Baotou Dongbao Bio-Tech Co.,Ltd announced on 24 April 2025 the profit distribution proposal for 2024 as follows: Cash dividend/10 shares (tax included): CNY 0.250. Reported Earnings • Apr 24
First quarter 2025 earnings released: EPS: CN¥0.032 (vs CN¥0.044 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.032 (down from CN¥0.044 in 1Q 2024). Revenue: CN¥188.0m (down 22% from 1Q 2024). Net income: CN¥19.0m (down 27% from 1Q 2024). Profit margin: 10% (in line with 1Q 2024). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Announcement • Apr 24
Baotou Dongbao Bio-Tech Co.,Ltd, Annual General Meeting, May 15, 2025 Baotou Dongbao Bio-Tech Co.,Ltd, Annual General Meeting, May 15, 2025, at 14:30 China Standard Time. Location: The Company's Meeting Room, Baotou, Inner Mongolia China Announcement • Mar 31
Baotou Dongbao Bio-Tech Co.,Ltd to Report Q1, 2025 Results on Apr 24, 2025 Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report Q1, 2025 results on Apr 24, 2025 Announcement • Jan 07
Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239) announces an Equity Buyback for CNY 100 million worth of its shares. Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The shares will be repurchased at no more than CNY 8 per share. The purpose of the program is to use the repurchased shares for equity incentives or employee stock ownership plans. If the Company fails to use up all repurchased shares within three years after the announcement of the implementation results of this share repurchase and the share change, the unused repurchased shares will be cancelled according to relevant procedures. The program will be funded from the Company’s own funds and/or self-raised funds. The program is subject to approval from shareholders. The program will be valid for 12 months. Announcement • Dec 31
Baotou Dongbao Bio-Tech Co.,Ltd to Report Fiscal Year 2024 Results on Apr 24, 2025 Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report fiscal year 2024 results on Apr 24, 2025 Valuation Update With 7 Day Price Move • Dec 30
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥6.10, the stock trades at a trailing P/E ratio of 39.8x. Average trailing P/E is 36x in the Chemicals industry in China. Total loss to shareholders of 13% over the past three years. Reported Earnings • Oct 28
Third quarter 2024 earnings released: EPS: CN¥0.025 (vs CN¥0.051 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.025 (down from CN¥0.051 in 3Q 2023). Revenue: CN¥188.8m (down 12% from 3Q 2023). Net income: CN¥14.9m (down 51% from 3Q 2023). Profit margin: 7.9% (down from 14% in 3Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Announcement • Sep 30
Baotou Dongbao Bio-Tech Co.,Ltd to Report Q3, 2024 Results on Oct 28, 2024 Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report Q3, 2024 results on Oct 28, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to CN¥5.58, the stock trades at a trailing P/E ratio of 31.2x. Average trailing P/E is 30x in the Chemicals industry in China. Total loss to shareholders of 12% over the past three years. Reported Earnings • Aug 28
Second quarter 2024 earnings released: EPS: CN¥0.043 (vs CN¥0.057 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.043 (down from CN¥0.057 in 2Q 2023). Revenue: CN¥202.5m (down 22% from 2Q 2023). Net income: CN¥25.4m (down 25% from 2Q 2023). Profit margin: 13% (in line with 2Q 2023). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. New Risk • Jul 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Announcement • Jun 29
Baotou Dongbao Bio-Tech Co.,Ltd to Report First Half, 2024 Results on Aug 28, 2024 Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report first half, 2024 results on Aug 28, 2024 Board Change • Jun 01
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 2 experienced directors. 3 highly experienced directors. GM & Director Fang Liu is the most experienced director on the board, commencing their role in 2000. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Declared Dividend • May 27
Dividend reduced to CN¥0.022 Dividend of CN¥0.022 is 15% lower than last year. Ex-date: 31st May 2024 Payment date: 31st May 2024 Dividend yield will be 0.4%, which is lower than the industry average of 2.6%. Sustainability & Growth Dividend is well covered by both earnings (11% earnings payout ratio) and cash flows (20% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 21% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Announcement • May 25
Baotou Dongbao Bio-Tech Co.,Ltd Announced 2023 Final Cash Distribution Plan on A Shares, Payable on 31 May 2024 Baotou Dongbao Bio-Tech Co.,Ltd announced 2023 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included) of CNY 0.22000000. Record date: 30 May 2024. Ex-date: 31 May 2024. Payment date: 31 May 2024. Valuation Update With 7 Day Price Move • May 10
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥6.25, the stock trades at a trailing P/E ratio of 30.9x. Average trailing P/E is 35x in the Chemicals industry in China. Total loss to shareholders of 14% over the past three years. Announcement • Apr 24
Baotou Dongbao Bio-Tech Co.,Ltd, Annual General Meeting, May 14, 2024 Baotou Dongbao Bio-Tech Co.,Ltd, Annual General Meeting, May 14, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Baotou, Inner Mongolia China Reported Earnings • Apr 24
First quarter 2024 earnings released: EPS: CN¥0.044 (vs CN¥0.053 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.044 (down from CN¥0.053 in 1Q 2023). Revenue: CN¥241.8m (down 7.5% from 1Q 2023). Net income: CN¥26.0m (down 17% from 1Q 2023). Profit margin: 11% (down from 12% in 1Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Buy Or Sell Opportunity • Apr 08
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 17% to CN¥5.07. The fair value is estimated to be CN¥6.40, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 63%. Announcement • Mar 30
Baotou Dongbao Bio-Tech Co.,Ltd to Report Q1, 2024 Results on Apr 26, 2024 Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report Q1, 2024 results on Apr 26, 2024 Buy Or Sell Opportunity • Mar 22
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 15% to CN¥5.10. The fair value is estimated to be CN¥6.40, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 63%. Buy Or Sell Opportunity • Mar 05
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 21% to CN¥5.10. The fair value is estimated to be CN¥6.44, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 63%. New Risk • Feb 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Feb 28
Investor sentiment improves as stock rises 33% After last week's 33% share price gain to CN¥6.01, the stock trades at a trailing P/E ratio of 30.5x. Average trailing P/E is 29x in the Chemicals industry in China. Total returns to shareholders of 9.0% over the past three years. Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to CN¥4.44, the stock trades at a trailing P/E ratio of 22.5x. Average trailing P/E is 28x in the Chemicals industry in China. Total loss to shareholders of 14% over the past three years. Buy Or Sell Opportunity • Feb 01
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 26% to CN¥4.76. The fair value is estimated to be CN¥5.98, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 63%. Announcement • Dec 30
Baotou Dongbao Bio-Tech Co.,Ltd to Report Fiscal Year 2023 Results on Apr 26, 2024 Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report fiscal year 2023 results on Apr 26, 2024 Reported Earnings • Nov 02
Third quarter 2023 earnings released: EPS: CN¥0.051 (vs CN¥0.05 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.051 (up from CN¥0.05 in 3Q 2022). Revenue: CN¥214.0m (down 6.8% from 3Q 2022). Net income: CN¥30.3m (up 1.5% from 3Q 2022). Profit margin: 14% (up from 13% in 3Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Announcement • Oct 01
Baotou Dongbao Bio-Tech Co.,Ltd to Report Q3, 2023 Results on Oct 30, 2023 Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report Q3, 2023 results on Oct 30, 2023 Reported Earnings • Aug 29
Second quarter 2023 earnings released: EPS: CN¥0.057 (vs CN¥0.058 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.057 (down from CN¥0.058 in 2Q 2022). Revenue: CN¥259.4m (up 4.5% from 2Q 2022). Net income: CN¥33.9m (down 1.1% from 2Q 2022). Profit margin: 13% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Announcement • May 12
Baotou Dongbao Bio-Tech Co.,Ltd Implements Final Profit Distribution Plan of A Shares for 2022, Payable on 19 May 2023 Baotou Dongbao Bio-Tech Co.,Ltd announced 2022 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included): CNY 0.26000000. Record date: 18 May 2023, Ex-date: 19 May 2023, Payment date: 19 May 2023. Reported Earnings • Mar 22
Full year 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.065 in FY 2021) Full year 2022 results: EPS: CN¥0.18 (up from CN¥0.065 in FY 2021). Revenue: CN¥943.4m (up 54% from FY 2021). Net income: CN¥109.4m (up 200% from FY 2021). Profit margin: 12% (up from 6.0% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Board Change • Nov 16
Less than half of directors are independent There are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. 2 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Deputy GM & Director Furong Wang is the most experienced director on the board, commencing their role in 2017. Independent Director Tao Ketao Erdun was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.05 (vs CN¥0.01 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.05 (up from CN¥0.01 in 3Q 2021). Revenue: CN¥229.7m (up 69% from 3Q 2021). Net income: CN¥29.8m (up 381% from 3Q 2021). Profit margin: 13% (up from 4.6% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 29
Second quarter 2022 earnings released: EPS: CN¥0.058 (vs CN¥0.005 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.058 (up from CN¥0.005 in 2Q 2021). Revenue: CN¥248.2m (up 79% from 2Q 2021). Net income: CN¥34.3m (up CN¥31.3m from 2Q 2021). Profit margin: 14% (up from 2.1% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jun 03
Baotou Dongbao Bio-Tech Co.,Ltd Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date: 10 June 2022 Baotou Dongbao Bio-Tech Co.,Ltd announced 2021 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included): CNY 0.06000000. Record date: 09 June 2022, Ex-date: 10 June 2022, Payment date: 10 June 2022. 10% withholding tax on cash dividend will be deducted in CNY within the cash dividend receivable. Please refer to below details: Tax on cash dividend/10 shares: CNY0.00600000(10% x CNY0.06000000) Net cash dividend/10 shares after tax: CNY0.05400000(CNY0.06000000- CNY0.00600000). Announcement • May 20
Baotou Dongbao Bio-Tech Co.,Ltd Approves Profit Distribution Plan for 2021 Baotou Dongbao Bio-Tech Co.,Ltd announced that at the Annual General Meeting held on 18 May 2022, approved cash dividend (tax included) of CNY 0.06000000 per ten shares for 2021. Valuation Update With 7 Day Price Move • May 02
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥7.03, the stock trades at a trailing P/E ratio of 75.1x. Average trailing P/E is 23x in the Chemicals industry in China. Total returns to shareholders of 56% over the past three years. Announcement • Apr 27
Baotou Dongbao Bio-Tech Co.,Ltd Proposes Cash Dividend for 2021 Baotou Dongbao Bio-Tech Co.,Ltd proposed cash dividend of CNY 0.06000000 (tax included) per 10 shares for 2021. Board Change • Apr 27
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 5 experienced directors. No highly experienced directors. Supervisor Tingting Yang is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Nov 01
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 5 experienced directors. No highly experienced directors. Supervisor Tingting Yang is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Oct 31
Third quarter 2021 earnings released: EPS CN¥0.01 (vs CN¥0.007 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥135.6m (up 19% from 3Q 2020). Net income: CN¥6.19m (up 64% from 3Q 2020). Profit margin: 4.6% (up from 3.3% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings. Board Change • Oct 02
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 5 experienced directors. No highly experienced directors. Supervisor Tingting Yang is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Aug 26
Second quarter 2021 earnings released: EPS CN¥0.005 (vs CN¥0.006 in 2Q 2020) The company reported a mediocre second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥138.5m (up 43% from 2Q 2020). Net income: CN¥2.92m (down 11% from 2Q 2020). Profit margin: 2.1% (down from 3.4% in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings. Reported Earnings • Apr 16
Full year 2020 earnings released: EPS CN¥0.035 (vs CN¥0.07 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥448.8m (down 8.7% from FY 2019). Net income: CN¥18.5m (down 48% from FY 2019). Profit margin: 4.1% (down from 7.2% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Announcement • Mar 09
Baotou Dongbao Bio-Tech Co.,Ltd to Report Fiscal Year 2020 Results on Apr 23, 2021 Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report fiscal year 2020 results on Apr 23, 2021 Is New 90 Day High Low • Jan 29
New 90-day low: CN¥4.84 The company is down 27% from its price of CN¥6.64 on 30 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 22% over the same period. Is New 90 Day High Low • Jan 11
New 90-day low: CN¥5.13 The company is down 30% from its price of CN¥7.38 on 13 October 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period. Is New 90 Day High Low • Dec 15
New 90-day high: CN¥7.56 The company is up 3.0% from its price of CN¥7.34 on 15 September 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 6.0% over the same period. Is New 90 Day High Low • Nov 26
New 90-day low: CN¥5.83 The company is down 4.0% from its price of CN¥6.06 on 28 August 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 8.0% over the same period. Reported Earnings • Oct 30
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥22.3m, down 37% from the prior year. Total revenue was CN¥453.8m over the last 12 months, down 3.4% from the prior year. Announcement • Jul 23
Baotou Dongbao Bio-Tech Co., Ltd. to Report First Half, 2020 Results on Aug 18, 2020 Baotou Dongbao Bio-Tech Co., Ltd. announced that they will report first half, 2020 results on Aug 18, 2020